Mark Davis

Exousia Pro $MAJI Shareholder Update: We are pleased to report a significant legal victory that supports our commitment to maximizing shareholder value. Following the hearing on December 16, 2025, the Court issued a favorable ruling, DENYING the Motion to Dismiss filed by Don Steinberg and Kimberly Carlson. This decision validates the strength of our claims and allows us to aggressively move forward to pursue justice on behalf of our shareholders. We remain dedicated to a positive and decisive outcome.

$MAJI we are waiting for our official notification from the FDA before we make any formal announcement on our Orphan Drug Application.  We do not want to jeopardize any future applications we have planned. This is a very exciting time for the Company, stay tuned for more updates.

$MAJI: We are exceptionally optimistic about the commercialization path for our CBD-loaded exosome technology. Our President, Matt Dwyer, leverages years of specialized executive experience and established, high-level connections within the California cannabis sector, providing an immediate and strategic advantage. Following the scientific confirmation from our team, Mr. Dwyer initiated successful preliminary discussions with both U.S. and European buyers, validating the strong commercial interest. Sales will commence immediately upon receiving the compelling results of our IRB study, demonstrating the enhanced efficacy of our exosomes. These operations will be managed under a newly formed subsidiary, establishing a swift, scalable pathway to profitability in this multi-billion-dollar market.